| (210) | Number of the EPO application | 16728566 |
| (220) | Filing date of the EPO application | 2016.06.02 |
| (80) | EPO patent specification publication (B) | EPB nr. 22/2021, 2021.06.02 |
| (110) | EPO patent number | 3303334 |
| (21) | Number of the application | e 2018 0328 |
| (71) | Name(s) of applicant(s), code of the country | Principia Biopharma Inc., US; |
| (72) | Name(s) of inventor(s), code of the country | GOLDSTEIN David, US;
OWENS Timothy D., US; |
| (73) | Name(s) of owner(s), code of the country | Principia Biopharma Inc., US; |
| (54) | Title of the invention | Tyrosine kinase inhibitors |
| (13) | Kind-of-document code | A1 |
| (51) | International Patent Classification | C07D 471/04 (2006.01.01); C07D 473/34 (2006.01.01); A61K 31/437 (2006.01.01); A61K 31/52 (2006.01.01); A61P 35/00 (2006.01.01); A61P 37/00 (2006.01.01) |
| (19) | Country | US |
| (41) | Date of publication of the application | 2022.07.31 |
| (30) | Priority | 201562170547 P, 2015.06.03, US; 201562271689 P, 2015.12.28, US |
| (74) | Patent attorney | (Procedură) LAZICOV Tatiana, str. A. Pușkin nr. 33, ap. 73, MD-2012, Chișinau, Republica Moldova |
| (86) | International application | PCT/US2016/035588, 2016.06.02 |
| (87) | International publication | WO 2016/196840, 2016.12.08 |